EU-FUNDED
PROJECTS
1. UAB “Froceth” is implementing the project “Development of the product of autologous dendritic cells for the treatment of cancer and clinical research”.
UAB “Froceth” is implementing the project “Development of the product of autologous dendritic cells for the treatment of cancer and clinical research” that is co-financed from the support of the European Fund of the Regional Development provided according to means No. J05-LVPA-K “Intellect. Common scientific-business projects” of implementation of priority 1 “Encouragement of scientific research, experimental development and innovations” of the program for the acts of investments from the EU-Funds 2014–2020.
The goal of the project is to increase the innovative potential of the company.
During the project, the product of dendritic cells will be developed at the company, the cocktail of a few allogenic well-characterized ovary cancer cell lines will be used for the manufacturing, it will be spiked with additional unspecific adjuvant TLR4 for the activation of the immune system and the clinical research of this product will be carried out. The use of allogenic cell line lysates for the incubation of dendritic cells will allow including more patients, who are suitable for immunotherapy with dendritic cells, in the treatment of cancer.
The total value of the project is 1 089 451,63 EUR, the amount of support granted for the project is 672 698,02 EUR.
​
2. UAB “Froceth” is implementing the project “Immunomodelling for the diagnostics and treatment of infertility”
UAB “Froceth” is implementing the project “Immunomodelling for the diagnostics and treatment of infertility” that is co-financed from the support of the European Fund of the Regional Development provided according to means No. J05-LVPA-K “Intellect. Common scientific-business projects” of implementation of priority 1 “Encouragement of scientific research, experimental development and innovations” of the program for the acts of investments from the EU-Funds 2014–2020.
The goal of the project is to increase the innovative potential of the company.
During the project, the immunological infertility diagnostics system will be developed at the company and it will be possible to use it for the identification of the groups of infertile couples for that it is pointless to apply costly procedures of assisted insemination, which are often dangerous to women’s health, and the application of immunotherapeutic treatment would help to get children in the way that is harmless to women’s health, and the advanced therapy medicinal product (vaccine) will be used for the treatment of immunological infertility and marketed as a result of the implemented project.
The total value of the project is 1 198 950,66 EUR, the amount of support granted for the project is 920 340,51 EUR.
​
3. UAB “Froceth” is implementing the project “Development of the company’s activity in the installation of industrial biotechnologies”, No. 03.3.1-LVPA-K-841-02-0001.
The project is co-financed from the support of the European Fund of the Regional Development provided according to means No. 03.3.1-LVPA-K-841 “For the HIT industry LT+” of implementation of priority 3 “Encouragement of the competitive ability of small and medium-sized business” of the program for the acts of investments from the EU-Funds 2014–2020.
The total value of the project is 302 571 EUR, the amount of support granted for the project is 128 592 EUR.
The beginning of implementation of the project is June 2017 and the end is April 2019.
The goal of the project is the development of the activity by implementing industrial biotechnologies. During the project, it is planned to expand the present activity of the company – procure and install the industrial equipment of biotechnologies (high-impact technologies - HIT) – and, as a result, start the mass manufacturing of innovative products – highly-specific recombinant proteins.
​
4. UAB “Froceth” is implementing the project “Advanced therapy immune system-modulating medicinal products for the treatment of cancer” together with the National Cancer Institute.
The project is co-financed from the support of the European Fund of the Regional Development provided according to the program for the acts of investments from the EU-Funds 2014–2020.
During the project, it is planned to develop 3 autologous dendritic cell vaccines, which immune response would be modulated by using the exosomes for different localizations of cancer:
-
Autologous anti-cancer dendritic cell vaccine for the treatment of glioblastoma;
-
Autologous anti-cancer dendritic cell vaccine for the treatment of melanoma;
-
Autologous anti-cancer dendritic cell vaccine for the treatment of lung cancer.
1. Personalized Tissue Engineering Preparation for Arterial Regeneration (iPETRA)
Project Number: E! 115315
The aim of the iPETRA project is to develop a new regenerative medicine product, Personalized Tissue-Engineered Artery (P-TEA) grafts, for the treatment of peripheral arterial disease and to prepare for the first-ever human clinical trials. The iPETRA project aims to complete the pre-clinical phase of P-TEA transplant development.
The project will aim to develop and optimize the P-TEA production process and transfer it to good manufacturing practice (GMP), perform in vitro and in vivo pre-clinical studies, and prepare for clinical trials and the launch of a new product. The tasks of UAB Froceth in the project are related to the research, optimization and adaptation of the technological process of P-TEA production taking into account the requirements of GMP, supply of P-TEA for preclinical research.
The project is implemented together with international partners from Sweden: VERIGRAFT AB, RISE Research Institutes of Sweden, Sahlgrenska University Hospital.
Funding for the project under the EUROSTARS-2 program. In Lithuania, the project is being implemented with funding from the Ministry of Education, Science and Sports of the Republic of Lithuania to the Agency for Science, Innovation and Technology.